Q-omics provides the consensus-scored FOLH1 profile across patient tissues and cancer cell-line models. FOLH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FOLH1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FOLH1 RNA expression shows 17,487 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where FOLH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOLH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOLH1 survival associations across molecular data types. FOLH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOLH1 RNA expression–survival associations across cancer types. High FOLH1 expression shows unfavorable associations in KIRP, UVM and ACC, but favorable associations in KIRC, LIHC and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FOLH1 RNA expression.
This table summarizes FOLH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FOLH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOLH1 shows lower tumor expression in KIRP, KICH and BRCA and higher tumor expression in KIRC, THCA and COAD. The KIRC box plot shows higher FOLH1 RNA expression in tumor versus normal tissue (log2 FC = +1.900, t-test p < 0.001).
This table shows molecular features associated with FOLH1 in patient tissues and cancer cell lines. In patient samples, FOLH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOLH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
